Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled …

JC Soria, E Felip, M Cobo, S Lu, K Syrigos… - The lancet …, 2015 - thelancet.com
Background There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …
被引用次数：510 相关文章

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled …

JC Soria, E Felip, M Cobo, S Lu, K Syrigos, KH Lee… - The Lancet …, 2015 - Elsevier
Background There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled …

JC Soria, E Felip, M Cobo, S Lu… - The Lancet …, 2015 - pubmed.ncbi.nlm.nih.gov
Background There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled …

JC Soria, S Jean-Charles, E Felip… - Journal of Modern …, 2015 - journals.eco-vector.com
Background. There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled …

JC Soria, S Jean-Charles, E Felip… - Journal of Modern …, 2015 - journals.rcsi.science
Background. There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled …

JC Soria, E Felip, M Cobo, S Lu, K Syrigos… - The Lancet …, 2015 - europepmc.org
Background There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …
[HTML] edgccjournal.org

[HTML][HTML] Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised …

JC Soria, S Jean-Charles, E Felip… - Journal of Modern …, 2015 - edgccjournal.org
Background. There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): An open-label randomised controlled …

JC Soria, E Felip, M Cobo, L Shun, K Syrigos… - THE LANCET …, 2015 - cris.unibo.it
Background: There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled …

JC Soria, S Jean-Charles, E Felip… - Journal of Modern …, 2015 - modernonco.orscience.ru
Background. There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …

[引用][C] Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised …

JC Soria, E Felip, M Cobo, S Lu, K Syrigos… - The Lancet …, 2015 - cir.nii.ac.jp
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell
carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial | CiNii …